Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

About this update from Privia Health Group, Inc.

Amalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale. WILMINGTON, Del.--(BUSINESS WIRE)-- Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rates to 84% in 2024, exceeding national benchmarks and surpassing the National Colorectal Cancer Roundtable’s 80% screening goal. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303669651/en/Amalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale. With March recognized as Colorectal Cancer Awareness Month, the findings underscore the importance of scalable, data-driven approaches that help health systems close screening gaps and identify patients who might otherwise go undiagnosed. Launched in 2023 and expanded nationally in 2024, the program combined Amalgam’s clinical decision support and population health workflows with Exact Sciences’ Cologuard® test as a noninvasive screening option for eligible, average-risk patients aged 45 and older to enable scalable, low-burden CRC screening. Beyond screening performance, the case study highlights the program’s ability to operate at population scale. Key outcomes include: More than 42,000 patients engaged through automated outreach across two markets (subsequently scaled nationally to reach over 100,000 patients) Approximately 23,000 CRC screening orders processed within a 48-hour window, with minimal staff lift A 10% positivity rate, identifying more than 550 patients who required diagnostic follow-up (as of the time of the case study analysis) An additional 37% of the patients made doctor appointments after the outreach Automated standing orders, reviewed and approved by authorized care team members, that ensured screening access even for patients who did not respond to outreach The partnership ex...

View stock analysis, news, and events for Privia Health Group, Inc.